Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Rebif launched in Canada: first drug to delay disease progression in remitting-relapsing MS

Feb. 20, 1998

Selective dopamine D3 ligands described by P&U

Feb. 20, 1998

Neurocrine Biosciences describes compounds for increasing endogenous neuropeptide levels

Feb. 20, 1998

Warner-Lambert reveals new antipsychotic benzoxazinones

Feb. 20, 1998

Oxcarbazepine derivatives with potent anticonvulsant activity

Feb. 20, 1998

Betaseron slows progression of disability in secondary progressive MS

Feb. 19, 1998

Development of PNU-95666E moves ahead

Feb. 19, 1998

Hoechst prepares xanthines for cerebrovascular disorders

Feb. 19, 1998

Merck describes dopamine D4 receptor ligands with therapeutic potential

Feb. 18, 1998

tPA associated with neurotoxic effects in acute model of stroke

Feb. 17, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...